Glomerulonephritis
Therapeutic area
Nephrology
Rare disease
No
- Definition
- A renal disorder characterized by damage in the glomeruli. It may be acute or chronic, focal or diffuse, and it may lead to renal failure. Causes include autoimmune disorders, infections, diabetes, and malignancies.
- Genetic basis
- No
- Non-human condition
- No
- Rare disease
- No
- Listing at source
- Listed
- Condition name
- Glomerulonephritis
- Therapeutic area
- Nephrology
- glomerulonephritis
- glomerular nephritis
- glomerulonephritis (disease)
- Glomerulonephritis (IC-MPGN)
- Glomerulonephritis, Immunoglobulin A (IgA)
- nephritis of renal glomerulus
- renal glomerulus nephritis
- bright's disease
- Disease mechanisms
- Inflammatory
Sources for recorded values
- All therapeutic areas
- Nephrology
Sources for recorded values
- Severity
- Severe
- MONDO ID
- MONDO:0002462
- Parent condition
- MONDO:0001166
Related records
Broader conditions (9)
- Disease
- Disease by body system or component
- Disease by developmental or physiological process
- Glomerular disorder
- Human disease
- Inflammatory disease
- Kidney disorder
- Nephritis
- Urinary system disorder
Narrower conditions (34)
- Acute diffuse glomerulonephritis
- Acute poststreptococcal glomerulonephritis
- Acute proliferative glomerulonephritis
- Anti-basement membrane glomerulonephritis
- Autoimmune glomerulonephritis
- C3 glomerulonephritis
- Chronic rapidly progressive glomerulonephritis
- Complement 3 glomerulopathy
- Complement factor H deficiency
- Crescentic glomerulonephritis
- Dense deposit disease
- Diffuse glomerulonephritis
- Eosinophilic granulomatosis with polyangiitis
- Exudative glomerulonephritis
- Focal embolic glomerulonephritis
- Granulomatosis with polyangiitis
- Idiopathic membranous glomerulonephritis
- IgA glomerulonephritis
- Immune-complex glomerulonephritis
- Immunoglobulin-mediated membranoproliferative glomerulonephritis
Trials (105)
- A Dose Escalation Study of Long-acting ACTH Gel in Membranous Nephropathy
- A Phase 3 Blinded Study of JADE101 in Participants With Immunoglobulin A Nephropathy
- A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy
- A Study of JADE101 in Participants With Immunoglobulin A Nephropathy
- A Study of Mezagitamab in Adults With Primary Immunoglobulin A Nephropathy Receiving Stable Background Therapy
- A Study of Rituximab in Frontline Therapy for Glomerulonephritis
- A Study of the Antioxidant Probucol Combined With Valsartan in Patients With IgA Nephropathy
- A Study of the Safety and Activity of Sparsentan for the Treatment of Patients With Immunoglobulin A Nephropathy
- A Study of TRPC5 Channel Inhibitor in Patients With Diabetic Nephropathy, Focal Segmental Glomerulosclerosis, and Treatment-Resistant Minimal Change Disease
- A Study of Zigakibart in Adults With IgA Nephropathy
- A Study to Assess Effectiveness and Safety of Efgartigimod in Chinese Patients With Lupus Nephritis (ZL-1103-013)
- A Study to Assess Effectiveness and Safety of Efgartigimod in Chinese Patients with Primary Membranous Nephropathy (ZL-1103-014)
- A Study to Determine if BHV-1400 is Effective and Safe in Adults With IgA Nephropathy
- A Study to Evaluate the Effect of Tacrolimus and Corticosteroid Combination Therapy in Patients With Minimal Change Nephrotic Syndrome
- Abatacept and Cyclophosphamide Combination Therapy for Lupus Nephritis
- ACTHAR GEL for Sarcoidosis-Associated Calcium Dysregulation: An Open-label Pilot Study
- Adrenocorticotropic Hormone in Membranous Nephropathy
- Affection of Renal and Urinary System in IBD Patients
- Aliskiren for Immunoglobulin A (IgA) Nephropathy
- Aliskiren in Patients With Idiopathic Membranous Nephropathy
Approved drugs (4)
- Chlorothiazide
- Chlorothiazide sodium
- Chlorthalidone
- Hydrochlorothiazide
Drugs in development (25)
- Corticotropin Phase 1
- Cyclophosphamide Phase 2
- Danicopan Phase 1
- Dapagliflozin propanediol Phase 2
- Daratumumab Phase 2
- Dexamethasone Phase 2
- Empagliflozin Phase 3
- Felzartamab Phase 2
- Finerenone Phase 2
- Iptacopan Phase 2
- Iptacopan hydrochloride Phase 1
- Lisinopril anhydrous Phase 2
- Methotrexate Phase 2
- Methylprednisolone Phase 2
- Methylprednisolone sodium succinate Phase 3
- Mezagitamab Phase 1
- Narsoplimab Phase 2
- Obinutuzumab Phase 2
- Olmesartan medoxomil Phase 2
- Pentoxifylline Phase 3